Business Context and Reporting Period
Company: iBio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 25, 2020
Reporting Period: Single event date (November 25, 2020)
iBio, Inc., a Delaware corporation, reported the entry into a new material definitive agreement and the termination of a prior agreement regarding the sale of its common stock.
Key Financial Metrics and Agreements
This filing details capital raising mechanisms rather than operational financial performance. Key figures include:
- New Offering Capacity: Up to $100,000,000 in aggregate offering price under a new "at the market" program.
- Sales Agent Compensation: Up to 3.0% of the gross sales price of shares sold.
- Expense Reimbursement: Up to $50,000 for the sales agent's expenses (including legal fees).
- Prior Program Proceeds: Approximately $72 million in gross proceeds from the terminated agreement.
- Prior Program Volume: 30,184,399 shares of common stock issued and sold.
Note: The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes Versus Prior Period
The primary material change is the replacement of the company's equity distribution partner and agreement:
- Termination: The Equity Distribution Agreement with UBS Securities LLC (dated June 17, 2020, as amended) was terminated effective November 25, 2020.
- New Agreement: A Controlled Equity Offering SM Sales Agreement was entered into with Cantor Fitzgerald & Co. on November 25, 2020.
- Registration Status: The new offering is subject to the effectiveness of a Form S-3 registration statement filed on November 25, 2020. The company provided no assurance regarding the effectiveness of this statement.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The company retains full discretion over the new offering. It has no obligation to sell any shares and may suspend solicitation at any time. The company will set parameters for sales, including share count, timing, daily limits, and minimum price thresholds.
Risks and Contingencies:
- Registration Risk: The new sales program is contingent upon the SEC declaring the Form S-3 registration statement effective.
- Termination Risk: The Sales Agreement may be terminated by either party for any reason, or by the Sales Agent in the event of a material adverse change in the company.
- Market Conditions: Sales are subject to market conditions and the company's ability to set favorable pricing parameters.
Important Facts for Investor Verification
- Verify the effectiveness status of the Form S-3 registration statement (File No. 333-250973) to confirm if the $100 million offering is active.
- Monitor future filings for actual share issuances and proceeds generated under the new Cantor Fitzgerald agreement.
- Review the impact of the 3.0% sales commission and expense reimbursements on net capital raised.
- Confirm the total outstanding share count following the 30,184,399 shares issued under the prior UBS agreement.